Zymeworks Completes Theravance Biopharma Acquisition to Boost Biotech Revenue

Key Facts

1Zymeworks announced the completion of its previously announced acquisition of Theravance Biopharma.

2Theravance Biopharma is now part of Zymeworks, advancing the strategy to build a diversified revenue-generating biotechnology company.

In a move reflecting the accelerating pace of consolidation within the healthcare sector, Zymeworks announced the completion of its previously announced acquisition of Theravance Biopharma. According to reports, Theravance Biopharma is now fully integrated into Zymeworks, advancing the parent company's strategy to build a diversified, revenue-generating biotechnology entity. This integration is designed to combine innovative research and development with established commercial and royalty-based cash flows.

The transaction comes as biotech firms increasingly seek to bolster their portfolios with immediate revenue streams, which Theravance provides through its existing royalty interests. Per market data, ZYME shares closed at $27.57 on September 22, 2026, having reached a day high of $27.7. Meanwhile, TBPH shares closed at $17.03 on the same date, trading within a tight range between $17.03 and $17.08 during the session.

Looking ahead, Zymeworks is scheduled to host a conference call on September 28 to discuss the final transaction details. Based on price levels at the close of September 22, 2026, investors are watching if ZYME can maintain support above its recent low of $26.55. Additionally, market participants will monitor upcoming U.S. Initial Jobless Claims data for broader sentiment cues that could impact high-growth sectors like biotechnology.